Lead Product(s) : Dabigatran Etexilate Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dabigatran Etexilate Capsules (generic for Pradaxa®), is good at preventing blood clots that can cause a stroke or heart attack, but it can be very expensive and must be used carefully in patients with kidney problems.
Product Name : Dabigatran Etexilate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2022
Lead Product(s) : Dabigatran Etexilate Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dabigatran Etexilate Mesylate
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic Gets USFDA Nod for Generic Medication
Details : Dabigatran etexilate mesylate is an approved direct thrombin inhibitor, which is indicated for deep vein thrombosis and pulmonary embolism.
Product Name : Pradaxa-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 13, 2024
Lead Product(s) : Dabigatran Etexilate Mesylate
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dabigatran Etexilate Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic Pharmaceuticals gets USFDA final approval for Dabigatran Etexilate capsules
Details : Pradaxa-Generic (dabigatran etexilate) is a USFDA approved direct thrombin inhibitor, which is indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation.
Product Name : Pradaxa-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 19, 2024
Lead Product(s) : Dabigatran Etexilate Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dabigatran Etexilate Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dabigatran etexilate reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagul...
Product Name : Pradaxa-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 23, 2021
Lead Product(s) : Dabigatran Etexilate Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dabigatran Etexilate Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Positive opinion is based on a dedicated clinical pediatric program for dabigatran, including the DIVERSITY study,2 which supplements dabigatran's established and well-documented safety and efficacy profile in adults
Product Name : Pradaxa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : Dabigatran Etexilate Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
